22157.jpg
Global Dyslipidemia Disease Analysis 2020-2027 - Market is Poised to Resume Steady Growth Due to the Introduction of Novel Agents
March 23, 2021 08:03 ET | Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dyslipidemia" report has been added to ResearchAndMarkets.com's offering. The report estimates that in 2018, there were...
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
February 25, 2021 06:50 ET | Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
Madrigal logo.jpg
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
November 13, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
November 05, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
Madrigal logo.jpg
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
August 26, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020,...
CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care.
August 11, 2020 12:00 ET | Cardiometabolic Health Congress
Boca Raton, FL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care. CMHC West Live Online: Complexities in Cardiometabolic Care concluded...
Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
August 06, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and...
NLA LOGO - USE.png
National Lipid Association Releases Official Scientific Statement on Genetic Testing in Dyslipidemia
July 10, 2020 12:30 ET | National Lipid Association
JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))
December 18, 2019 06:50 ET | Madrigal Pharmaceuticals, Inc.
-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
December 10, 2019 23:57 ET | Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the...